文献速递糖尿病

精准糖尿病:从单基因糖尿病中学习

Precision diabetes: learning from monogenic diabetes.
PubMed 文献 · Diabetologia · 2017-03-17

本综述探讨单基因糖尿病(MODY和新生儿糖尿病)中精准医学方法成功的原因,并分析其对2型糖尿病的启示。单基因糖尿病的分子遗传学可定义离散的病因亚型,对治疗和预测临床特征有深远影响;而2型糖尿病具有重叠的多基因易感性和潜在病因,难以定义对治疗有显著意义的离散临床亚型。单基因糖尿病的经验提示,2型糖尿病成功采用精准糖尿病方法需要基于常规临床数据组合的简单、快速、易获取的分层策略,而非依赖新技术。

要点

  • 单基因糖尿病的精准医学成功源于分子遗传学可定义离散病因亚型,对治疗和预测临床特征有深远影响。
  • 2型糖尿病具有重叠的多基因易感性和潜在病因,难以定义对治疗有显著意义的离散临床亚型。
  • 新生儿糖尿病精准医学实施简单快速,基于单一临床标准(诊断年龄<6个月);MODY则因缺乏单一识别标准而更复杂缓慢,但诊断概率计算器和相关智能手机应用 greatly assisted。

核心结论

  • 单基因糖尿病中精准医学方法取得成功,其经验提示2型糖尿病成功采用精准糖尿病方法需要基于常规临床数据组合的简单、快速、易获取的分层策略,而非依赖新技术。
  • 分析常规临床实践和试验中已有的临床数据可能为2型糖尿病精准医学提供早期成功。

研究设计与样本

  • 综述,探讨单基因糖尿病(MODY和新生儿糖尿病)中精准医学方法成功的原因及其对2型糖尿病的可能启示。

主要发现

  • 单基因糖尿病的分子遗传学可定义离散病因亚型,对糖尿病治疗有深远影响,并可预测相关临床特征的未来发展,允许早期预防或支持治疗。
  • 2型糖尿病具有重叠的多基因易感性和潜在病因,难以定义对治疗有显著意义的离散临床亚型。
  • 新生儿糖尿病精准医学实施简单快速,基于单一临床标准(诊断年龄<6个月)。
  • MODY精准医学实施更复杂缓慢,因缺乏识别患者的单一标准,但诊断概率计算器和相关智能手机应用 greatly assisted。

关键数值与推荐

  • 新生儿糖尿病精准医学实施基于单一临床标准:诊断年龄<6个月。
  • MODY精准医学实施由诊断概率计算器和相关智能手机应用 greatly assisted。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The precision medicine approach of tailoring treatment to the individual characteristics of each patient or subgroup has been a great success in monogenic diabetes subtypes, MODY and neonatal diabetes. This review examines what has led to the success of a precision medicine approach in monogenic diabetes (precision diabetes) and outlines possible implications for type 2 diabetes. For monogenic diabetes, the molecular genetics can define discrete aetiological subtypes that have profound implications on diabetes treatment and can predict future development of associated clinical features, allowing early preventative or supportive treatment. In contrast, type 2 diabetes has overlapping polygenic susceptibility and underlying aetiologies, making it difficult to define discrete clinical subtypes with a dramatic implication for treatment. The implementation of precision medicine in neonatal diabetes was simple and rapid as it was based on single clinical criteria (diagnosed <6 months of age). In contrast, in MODY it was more complex and slow because of the lack of single criteria to identify patients, but it was greatly assisted by the development of a diagnostic probability calculator and associated smartphone app. Experience in monogenic diabetes suggests that successful adoption of a precision diabetes approach in type 2 diabetes will require simple, quick, easily accessible stratification that is based on a combination of routine clinical data, rather than relying on newer technologies. Analysing existing clinical data from routine clinical practice and trials may provide early success for precision medicine in type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. Diabetologia. 2017. PMID: 28314945. doi:10.1007/s00125-017-4226-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。